Abstract
The antimicrobial activity of a new quinolone, Bay Y3118, was determined against 326 strains of anaerobic bacteria and compared with the activities of ampicillin-sulbactam, cefotetan, clindamycin, imipenem, metronidazole, and sparfloxacin. The National Committee for Clinical Laboratory Standards-approved Wadsworth agar dilution technique with Brucella-laked blood agar was used throughout the study. Breakpoints used to determine the percent susceptible were 2 micrograms/ml for Bay Y3118 and sparfloxacin, 4 micrograms/ml for clindamycin, 8 micrograms/ml for imipenem, 16 micrograms/ml for metronidazole and ampicillin-sulbactam, and 32 micrograms/ml for cefotetan. Species tested included Bacteroides fragilis (57 strains), other B. fragilis group species (79 strains), Bacteroides gracilis (10 strains), other Bacteroides spp. (9 strains), Prevotella spp. (30 strains), Porphyromonas spp. (9 strains), Fusobacterium spp. (36 strains), Bilophila wadsworthia (14 strains), Clostridium spp. (36 strains), Peptostreptococcus spp. (20 strains), and gram-positive non-spore-forming rods (26 strains). Bay Y3118 inhibited all but 1 of 326 anaerobic bacteria tested at the breakpoint level or lower.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
